TSKS Inhibitors
Chemical inhibitors of TSKS work through various mechanisms to decrease the kinase activity of the protein. Staurosporine is a broad-spectrum inhibitor that targets serine/threonine kinases by competing with ATP binding sites on these enzymes. As TSKS is a serine/threonine kinase, staurosporine can directly inhibit its activity by preventing the phosphorylation events that TSKS carries out. Similarly, Bisindolylmaleimide I, which selectively targets protein kinase C (PKC), can reduce the phosphorylation of proteins that are either substrates or regulators of TSKS, leading to a decrease in TSKS activity. LY294002 and Wortmannin, both inhibitors of PI3K, can decrease the activation of Akt, a kinase that phosphorylates numerous serine/threonine kinases. If TSKS is regulated by Akt-mediated phosphorylation, the inhibition of this pathway by either LY294002 or Wortmannin can result in reduced TSKS activity.
Further modulating the activity of TSKS, H-89, an inhibitor of protein kinase A (PKA), can lower the phosphorylation of proteins that may interact with or control TSKS, thus diminishing the kinase's activation. Rapamycin, by inhibiting the mTOR pathway, can lead to a reduction in the function of serine/threonine kinases downstream of mTOR, which includes TSKS. SP600125 and SB203580, which inhibit JNK and p38 MAP kinase respectively, can also decrease TSKS activity. They do this by reducing the phosphorylation of proteins that could be part of the same signaling networks as TSKS. Furthermore, U0126 and PD98059, both targeting MEK, can prevent the activation of the ERK pathway, which in turn can reduce TSKS activity by lowering regulatory phosphorylation events on associated proteins. Lastly, PP2, as an Src family kinase inhibitor, can indirectly diminish TSKS activity through its regulation of various proteins, which may include serine/threonine kinases, and GF109203X, by inhibiting PKC, can also lead to a reduction in the function of TSKS.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases, including many serine/threonine kinases. TSKS is a serine/threonine kinase, and staurosporine's broad kinase inhibition profile suggests that it would inhibit TSKS by competing with ATP for binding to the kinase domain, thus preventing phosphorylation events that TSKS conducts. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I selectively inhibits protein kinase C (PKC), and since PKC can phosphorylate a wide array of substrates, including serine/threonine kinases, its inhibition might reduce phosphorylation levels on proteins that could be substrates or regulators of TSKS, thereby decreasing TSKS activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of the PI3K/Akt pathway. Since Akt can phosphorylate and regulate multiple serine/threonine kinases, inhibiting this pathway could lead to a decrease in the activation and function of TSKS if TSKS is regulated by Akt-mediated phosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and by inhibiting mTOR, which is a central regulator of cell growth and proliferation, it might lead to a decrease in the activity of downstream serine/threonine kinases, including TSKS, by reducing overall signaling through this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 may reduce the phosphorylation of downstream targets that could interact with or regulate TSKS, leading to a decrease in TSKS kinase activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase. Inhibition of p38 MAP kinase can reduce the phosphorylation of downstream substrates that may regulate or be involved in the same signaling pathways as TSKS, which could result in decreased TSKS activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. Inhibiting MEK1/2 would prevent the activation of ERK, potentially reducing the phosphorylation and activation of substrates that could interact with or regulate TSKS, leading to inhibition of TSKS activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, and by blocking PI3K activity, it could decrease Akt phosphorylation and subsequent signaling events that may regulate TSKS activity, resulting in functional inhibition of TSKS. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 specifically inhibits MEK, which, like U0126, would prevent the activation of the ERK pathway. Inhibiting this pathway could reduce regulatory phosphorylation events on proteins that are involved in the same signaling cascades as TSKS, thus inhibiting TSKS. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases can phosphorylate and regulate a variety of proteins, including serine/threonine kinases. Inhibition of Src family kinases could indirectly decrease TSKS activity by affecting its regulation or interaction with other proteins. | ||||||